{"id":9151,"date":"2021-02-18T00:00:00","date_gmt":"2021-02-18T00:00:00","guid":{"rendered":""},"modified":"2021-03-01T16:40:08","modified_gmt":"2021-03-01T16:40:08","slug":"baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-results-from-a-randomized-monotherapy-phase-3-trial-in-the-united-states-and-canada-breeze-ad5","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2021\/02\/18\/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-results-from-a-randomized-monotherapy-phase-3-trial-in-the-united-states-and-canada-breeze-ad5\/","title":{"rendered":"Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5)."},"content":{"rendered":"<p>Baricitinib, an oral, selective Janus kinase (JAK)1\/JAK2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults.To evaluate the efficacy and safety of baricitinib monotherapy in a North American [&#8230;]\n","protected":false},"excerpt":{"rendered":"<p>Baricitinib, an oral, selective Janus kinase (JAK)1\/JAK2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults.To evaluate the efficacy and safety of baricitinib monotherapy in a North American &#8230;<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[86],"tags":[],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9151"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=9151"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9151\/revisions"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=9151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=9151"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=9151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}